Home | Clinical Care | Research | Training | Division Activities

Education and Training:

B.S., Biology, Wright State University, Dayton, OH (1982)

M.D., The Ohio State University, Columbus, OH (1986)

Internship, Department of Medicine, Duke University (1986-87)

Residency, Department of Medicine, Duke University (1987-89)

Fellowship, Division of Oncology, University of Washington, Seattle, (1989-94)

C. Anthony Blau, M.D.
Professor of Medicine, Division of Hematology
University of Washington School of Medicine
Co-Director, University of Washington Institute for Stem Cell and Regenerative Medicine
Director, Center for Cancer Innovation
Office Address:
Institute for Stem Cell and Regenerative Medicine
University of Washington, Campus Box 358056
850 Republican Street, Rm N536
Seattle, WA 98109

Phone:  (206) 685-6873
Fax:      (206) 221-6034
E-mail:  tblau@u.washington.edu

Center for Cancer Innovation:  http://cci.washington.edu/
Institute for Stem Cell and Regenerative Medicine:  https://depts.washington.edu/iscrm
Blau Lab:  https://depts.washington.edu/blaulab


CURRENT CLINICAL INTERESTS
Triple negative breast cancer


CURRENT RESEARCH INTERESTS
Personalized approaches to cancer treatment


RESEARCH DESCRIPTION
The University of Washington Center for Cancer Innovation is inspired by patients with incurable forms of cancer and is powered by a diverse team of experts devoted to doing their best for patients. Our mission is two fold: bring the best care possible to individual patients; and to learn from these patients to better understand targetable features of aggressive tumors.

At the heart of our approach is a re-definition of what it means to "do our best" for patients with advanced cancer. Our individualized or personalized approach focuses the efforts of a diverse team of clinicians, biologists, data scientists, and computer scientists on an individual patients disease. We have begun an initial clinical trial focusing on patients with advanced breast cancer and are close to launching a second trial focusing on patients with advanced AML.


SELECTED PUBLICATIONS

Blau CA. Can intensive longitudinal monitoring of individuals advance cancer research?  Oncologist 2012;17(5):587-9. PMID:22523197 PMCID: PMC3360897.

Blau CA, Liakopoulou E. Can we deconstruct cancer, one patient at a time?  Trends in Genetics 2013 29:6-10. PMID:23102584. PMC Journal (in process).

Zare H, Wang J, Hu A, Weber K, Smith J, Nickerson D, Song CZ, Witten D, Blau CA , Noble WS.   Inferring clonal composition from multiple sections of a breast cancer. NPLOS Computational Biology (accepted for publication).

Miller CP, Thorpe J, Kortum A, Coy CM, Cheng W-Y, Yang T-H O, Anastassiou D, Beatty JD, Urban ND, Blau CA. JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors.  Cancer Immunol. Res. 2014;2:301-6. PMID: 24764577. PMCID: PMC4001121.